FDA's Peptide Review Is Here: What Pharmacies, Providers, and Product Companies Need to Know
FDA / PCAC — official records & coverage — FDA's Peptide Review Is Here: What Pharmacies, Providers, and Product Companies Need to Know
Channel: Frier Levitt · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=uV6zXVzD-V4
What this video covers
Good afternoon and welcome to today’s presentation on the FDA’s July peptide review and what the PCAT committee means for peptide compounding. Couldn’t be a better topic for the uh the latest developments that are happening. And so I’m excited to get into some of the unique things that are going to happen over the next couple days. We are a boutique healthcare life science law firm located in Pine Brook, New Jersey and New York uh city.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Good afternoon and welcome to today’s presentation on the FDA’s July peptide review and what the PCAT committee means for peptide compounding.
- So if a peptide is 41 amino acids long, you would not be able to it would be unlawful to attempt to uh compound that that drug or that biologic uh in FDA’s terms.
- But the FDA has identified significant safety risk risks related to the use of these subjects, these substances in compounding pending further evaluation.
- These include BPC157, TB500, KPV, SEMAX, and uh MOTSC.
- And this is being promoted for wound healing and uh KPV uh proposed not to be added because no human clinical studies for the proposed use exist.
- No human clinical studies uh no evidence uh any outsourcing facility has compounded it and uh it’s on the water prohibited list.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.